- Home
- BNR vs PIII Comparison
BNR vs PIII Comparison
Compare BNR & PIII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNR
- PIII
- Stock Information
- Founded
- BNR 2014
- PIII 2015
- Country
- BNR China
- PIII United States
- Employees
- BNR N/A
- PIII N/A
- Industry
- BNR Medical Specialities
- PIII Medical/Nursing Services
- Sector
- BNR Health Care
- PIII Health Care
- Exchange
- BNR Nasdaq
- PIII Nasdaq
- Market Cap
- BNR 29.1M
- PIII 21.4M
- IPO Year
- BNR 2020
- PIII N/A
- Fundamental
- Price
- BNR $3.80
- PIII $6.10
- Analyst Decision
- BNR
- PIII Buy
- Analyst Count
- BNR 0
- PIII 2
- Target Price
- BNR N/A
- PIII $16.25
- AVG Volume (30 Days)
- BNR 36.5K
- PIII 3.9K
- Earning Date
- BNR 08-21-2025
- PIII 08-06-2025
- Dividend Yield
- BNR N/A
- PIII N/A
- EPS Growth
- BNR N/A
- PIII N/A
- EPS
- BNR N/A
- PIII N/A
- Revenue
- BNR $72,112,038.00
- PIII $1,485,192,000.00
- Revenue This Year
- BNR $136.32
- PIII N/A
- Revenue Next Year
- BNR N/A
- PIII $6.01
- P/E Ratio
- BNR N/A
- PIII N/A
- Revenue Growth
- BNR 0.53
- PIII 9.79
- 52 Week Low
- BNR $2.18
- PIII $6.00
- 52 Week High
- BNR $7.90
- PIII $32.54
- Technical
- Relative Strength Index (RSI)
- BNR 61.98
- PIII 37.90
- Support Level
- BNR $3.06
- PIII $6.25
- Resistance Level
- BNR $3.50
- PIII $6.69
- Average True Range (ATR)
- BNR 0.23
- PIII 0.20
- MACD
- BNR 0.03
- PIII 0.07
- Stochastic Oscillator
- BNR 84.78
- PIII 13.51
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.